These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 30447687)

  • 1. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
    Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
    Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
    Olgar Y; Turan B
    Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.
    Lahnwong C; Palee S; Apaijai N; Sriwichaiin S; Kerdphoo S; Jaiwongkam T; Chattipakorn SC; Chattipakorn N
    Cardiovasc Diabetol; 2020 Jun; 19(1):91. PubMed ID: 32539724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Titin and CK2α are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats.
    Durak A; Bitirim CV; Turan B
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):487-501. PubMed ID: 32377826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
    Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
    Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
    Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
    Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
    Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
    Shi L; Zhu D; Wang S; Jiang A; Li F
    Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca
    Durak A; Akkus E; Canpolat AG; Tuncay E; Corapcioglu D; Turan B
    Clin Exp Pharmacol Physiol; 2022 Jan; 49(1):46-59. PubMed ID: 34519087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylene Blue Counteracts H
    Cheung JY; Wang J; Zhang XQ; Song J; Davidyock JM; Prado FJ; Shanmughapriya S; Worth AM; Madesh M; Judenherc-Haouzi A; Haouzi P
    Cardiovasc Toxicol; 2018 Oct; 18(5):407-419. PubMed ID: 29603116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
    Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
    Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction.
    Lin YW; Chen CY; Shih JY; Cheng BC; Chang CP; Lin MT; Ho CH; Chen ZC; Fisch S; Chang WT
    J Am Heart Assoc; 2021 Apr; 10(7):e019274. PubMed ID: 33749310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.
    Bode D; Semmler L; Wakula P; Hegemann N; Primessnig U; Beindorff N; Powell D; Dahmen R; Ruetten H; Oeing C; Alogna A; Messroghli D; Pieske BM; Heinzel FR; Hohendanner F
    Cardiovasc Diabetol; 2021 Jan; 20(1):7. PubMed ID: 33413413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.